Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL27529721 | 0.93 | NAAA (0.83) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL297171 | 0.93 | NAAA (0.68) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL50185 | 0.92 | NAAA (0.81) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL28545617 | 0.91 | NAAA (0.72) | NAAAHTTRAD52NPSR1FAAH | |
| Ethylene Glycol SCHEMBL27876555 | 0.91 | NAAA (0.72) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL27846296 | 0.91 | NAAA (0.72) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL2529381 | 0.91 | NAAA (0.72) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL15541848 | 0.91 | NAAA (0.72) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL2527736 | 0.91 | NAAA (0.72) | NAAAHTTRAD52NPSR1FAAH | |
| SCHEMBL376910 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047356-B | Method for refining eucommia ulmoides crude glue solution | 山东贝隆杜仲生物工程有限公司 | 2020-06-16 | — | — | CN | claimed |
| US-20160375078-A1 | TOPICAL COMPOSITION COMPRISING NATURAL INGREDIENTS FOR BRUISING OR HEMATOMA HEALING ON SKIN AND USE THEREOF | AMPHORA HOLDINGS, INC. | 2016-12-29 | — | — | US | claimed |
| EP-3076946-B1 | COMPOSITIONS COMPRISING ANTIOXIDANT, FLUID DISPENSERS, AND METHODS INVOLVING THE SAME | ALZET LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250127776-A1 | ORAL PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-04-24 | — | — | US | disclosed |
| US-20250057835-A1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-20 | — | — | US | disclosed |
| US-12097189-B1 | Pharmaceutical composition for modified release | ASTELLAS PHARMA INC. (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240293307-A1 | Compositions Comprising Antioxidant, Fluid Dispensers, and Methods Involving the Same | DURECT CORPORATION (US) | 2024-09-05 | — | — | US | disclosed |
| US-20230414512-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4218718-A2 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | Laboratory Skin Care, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11707451-B2 | Pharmaceutical composition for modified release | ASTELLAS PHARMA INC. (JP) | 2023-07-25 | — | — | US | disclosed |
| EP-2427178-B1 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | LABORATORY SKIN CARE INC (US) | 2023-01-04 | — | — | EP | disclosed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | disclosed |
| US-4203439-A | Osmotic system with volume amplifier for increasing amount of agent delivered therefrom | ALZA CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-4160452-A | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina | ALZA CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| US-4111201-A | OSMOTIC SYSTEM FOR DELIVERING SELECTED BENEFICIAL AGENTS HAVING VARYING DEGREES OF SOLUBILITY | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4111203-A | OSMOTIC SYSTEM WITH MEANS FOR IMPROVING DELIVERY KINETICS OF SYSTEM | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4111202-A | OSMOTIC SYSTEM FOR THE CONTROLLED AND DELIVERY OF AGENT OVER TIME | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4077407-A | POLYSACCHARIDES | ALZA CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707451-B2 | Pharmaceutical composition for modified release | SLC6A19, AASDHPPT, SLC6A15 | NAAA 657/4885HTT 608/4885RAD52 4762/4885 |
| US-20250127776-A1 | ORAL PHARMACEUTICAL COMPOSITION | LIPA, CYP2C19, PNLIP | NAAA 1821/4885HTT 1068/4885RAD52 4327/4885 |
| US-20250057835-A1 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND | CYP2C19, CYP2C18, CYP3A7 | NAAA 1341/4885HTT 347/4885RAD52 4538/4885 |
| US-12097189-B1 | Pharmaceutical composition for modified release | SLC6A19, SLC6A15, GART | NAAA 608/4885HTT 646/4885RAD52 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.